Antihypertensive Therapy in Preeclampsia: A Secondary Hospital Perspective on Prescribing Behavior and Patient Safety

Pramitha Esha Nirmala Dewi; Githa Fungie Galistiani; Aris Widayati

doi:10.24198/ijpst.v13i2.67628

Antihypertensive Therapy in Preeclampsia: A Secondary Hospital Perspective on Prescribing Behavior and Patient Safety

Pramitha Esha Nirmala Dewi, Githa Fungie Galistiani, Aris Widayati

Abstrak

Hypertensive disorders in pregnancy remain a leading cause of maternal and neonatal morbidity and mortality worldwide, including in Indonesia. Preeclampsia contributes significantly to maternal deaths due to uncontrolled blood pressure and inappropriate drug use. This study aims to evaluate the prescribing behavior, therapeutic outcomes, and safety of antihypertensive drugs used in preeclampsia management in secondary hospitals. A retrospective cohort study was conducted among 832 hospitalized patients with preeclampsia in Yogyakarta, Indonesia, from 2018 to 2024. Analytical and descriptive methods were employed to examine both patient characteristics and treatment variables. This study found that complete recommended therapy was predominantly administered among patients in the third trimester (100%) and those with gravida <3 (72.9%). Nifedipine was the most frequently prescribed drug (63.2%). In terms of effectiveness, nifedipine monotherapy achieved target blood pressure in 48.4% of patients, compared to 15.6% in methyldopa monotherapy, while combination therapy (nifedipine–methyldopa) achieved 6.1%. These findings are consistent with current clinical guidelines, where methyldopa is considered a safe first-line antihypertensive, while nifedipine serves as an effective alternative to achieve optimal maternal and fetal outcomes.

Kata Kunci

Drug safety; Hypertension; Pregnant women; Preeclampsia; Prescription pattern

Teks Lengkap:

PDF (English)

Referensi

Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: Risk factors, diagnosis, management, and the cardiovascular impact on the offspring. J Clin Med. 2019;8(10):1625.

Espinoza J, Vidaeff A, Pettker CM, Simhan H. Gestational hypertension and preeclampsia. Obstet Gynecol. 2020;135(6):e237-e260.

Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia 2014. Jakarta: Kementerian Kesehatan RI; 2014.

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.

Robillard PY, Boukerrou M, Dekker G, Scioscia M, Bonsante F, Boumahni B, et al. Risk factors for early and late onset preeclampsia in Reunion Island: Multivariate analysis of singleton and twin pregnancies. A 20-year population-based cohort of 2120 preeclampsia cases. Reprod Med. 2021;2(3):131-143.

Odigboegwu O, Pan LJ, Chatterjee P. Use of antihypertensive drugs during preeclampsia. Front Cardiovasc Med. 2018;5:50.

Perkumpulan Obstetri dan Ginekologi Indonesia. Pedoman nasional pelayanan kedokteran: diagnosis dan tata laksana pre-eklamsia. Jakarta: Perkumpulan Obstetri dan Ginekologi Indonesia; 2016.

Yani YA. Evaluasi penggunaan obat antihipertensi pasien preeklampsia di instalasi rawat inap RSUD Prof Dr WZ Johannes Kupang. CHMK Pharmaceutical Scientific Journal. 2021;4(1):242-248.

Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia 2021 [Internet]. Jakarta: Kementerian Kesehatan RI; 2021 [cited 2024 Jul 20]. Available from: https://kemkes.go.id/id/profil-kesehatan-indonesia-2021

Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia 2023 [Internet]. Jakarta: Kementerian Kesehatan RI; 2023 [cited 2024 Aug 5]. Available from: https://kemkes.go.id/id/profil-kesehatan-indonesia-2023

Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: Diagnosis, blood pressure goals, and pharmacotherapy: A scientific statement from the American Heart Association. Hypertension. 2022;79(2):e21-e41.

Husna N, Melinda C, Sugita R, Anggraeni R. Studi faktor risiko, pola pengobatan, dan luaran klinis pasien preeklampsia di RSUD Sleman Yogyakarta. Jurnal Sains Farmasi & Klinis. 2023;9:196.

English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;8:7-12.

Lopez-Jaramillo P, Barajas J, Rueda-Quijano SM, Lopez-Lopez C, Felix C. Obesity and preeclampsia: Common pathophysiological mechanisms. Front Physiol. 2018;9:1838.

Ramadhan MFY, Mulyani T, Ariyani H. Evaluation of the use of antihypertensive medicines in inpatient preeclampsia patients in Datu Sanggul Rantau Hospital. J Curr Pharm Sci. 2022;5(2):514-523.

Wei EK, Long T, Katz MH. Nine lessons learned from the COVID-19 pandemic for improving hospital care and health care delivery. JAMA Intern Med. 2021;181(9):1161-1163.

Hollenberg SM, Janz DR, Hua M, Malesker M, Qadir N, Rochwerg B, et al. COVID-19: Lessons learned, lessons unlearned, lessons for the future. Chest. 2022;162(6):1297-1305.

Bajpai D, Popa C, Verma P, Dumanski S, Shah S. Evaluation and management of hypertensive disorders of pregnancy. Kidney360. 2023;4(10):1512-1525.

Grewal J, Siu SC, Lee T, D'Souza R, Dvir M, Singer J, et al. Impact of beta-blockers on birth weight in a high-risk cohort of pregnant women with cardiovascular disease. J Am Coll Cardiol. 2020;75(21):2751-2752.

Ardissino M, Slob EAW, Rajasundaram S, Reddy RK, Woolf B, Girling J, et al. Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: A Mendelian randomization study. BMC Med. 2022;20(1):288.

Savadi B, Nalwarkar B, BM R. Study of serum electrolytes, calcium and magnesium in preeclampsia at a tertiary hospital in central Karnataka. Int J Clin Biochem Res. 2021;8(1):145-149.

Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia. Stroke. 2009;40(4):1169-1175.

Awaludin A, Rahayu C, Daud NAA, Zakiyah N. Antihypertensive medications for severe hypertension in pregnancy: A systematic review and meta-analysis. Healthcare (Basel). 2022;10(2):325.

Padda J, Khalid K, Colaco LB, Padda S, Boddeti NL, Khan AS, et al. Efficacy of magnesium sulfate on maternal mortality in eclampsia. Cureus. 2021;13(8):e17322.

Ansaldi Y, Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023;29(10):1249-1253.

Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: A current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581.

Cantarutti A, Rea F, Franchi M, Beccalli B, Locatelli A, Corrao G. Use of antibiotic treatment in pregnancy and the risk of several neonatal outcomes: A population-based study. Int J Environ Res Public Health. 2021;18(23):12650.

Orwa SA, Gudnadottir U, Boven A, Pauwels I, Versporten A, Vlieghe E, et al. Global prevalence of antibiotic consumption during pregnancy: A systematic review and meta-analysis. J Infect. 2024;89(2):106189. doi:10.1016/j.jinf.2024.106189.

Cardetti M, Rodríguez S, Sola A. Use (and abuse) of antibiotics in perinatal medicine. An Pediatr (Engl Ed). 2020;93(3):207.e1-207.e7.

D'Ambrosio V, Vena F, Scopelliti A, D'Aniello D, Savastano G, Brunelli R, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: A review. J Matern Fetal Neonatal Med. 2023;36(2):2253956.

Choi EY, Jeong HE, Noh Y, Choi A, Yon DK, Han JY, et al. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study. PLoS Med. 2023;20(2):e1004183.

Ajong AB, Yakum MN, Aljerf L, Ali IM, Mangala FN, Onydinma UP, et al. Association of hypertension in pregnancy with serum electrolyte disorders in late pregnancy among Cameroonian women. Sci Rep. 2023;13(1):20940.

Hurrell A, Busuulwa P, Webster L, Duhig K, Seed PT, Chappell LC, et al. Optimising timing of steroid administration in preterm pre-eclampsia. Pregnancy Hypertens. 2022;30:177-180.

Norman M, Piedvache A, Børch K, Huusom LD, Bonamy AE, Howell EA, et al. Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity among very preterm infants: Results from the EPICE cohort. JAMA Pediatr. 2017;171(7):678-686.

Chambali MA, Meylina L, Rusli R. Analisis efektivitas biaya penggunaan obat antihipertensi pada pasien preeklampsia di RSUD Abdul Wahab Sjahranie periode 2018. Proc Mulawarman Pharm Conf. 2019.

Katsi V, Svigkou A, Dima I, Tsioufis K. Diagnosis and treatment of eclampsia. J Cardiovasc Dev Dis. 2024;11(9):257.

Cífková R. Hypertension in pregnancy: A diagnostic and therapeutic overview. High Blood Press Cardiovasc Prev. 2023;30(4):289-303.

Duvekot JJ, Duijnhoven RG, van Horen E, Bax CJ, Bloemenkamp KW, Brussé IA, et al. Temporizing management vs immediate delivery in early-onset severe preeclampsia between 28 and 34 weeks of gestation (TOTEM study): An open-label randomized controlled trial. Acta Obstet Gynecol Scand. 2021;100(1):109-118.

Nirupama R, Divyashree S, Janhavi P, Muthukumar SP, Ravindra PV. Preeclampsia: Pathophysiology and management. J Gynecol Obstet Hum Reprod. 2021;50(2):101975.

Fakhir N, Masood H, Khanum W, Faisal J, Kanwal S, Afridi N. A comparison of tablet nifedipine with tablet methyldopa in controlling mild to moderate pregnancy-induced hypertension (PIH). Pak J Med Health Sci. 2020;14(3):1469-1471.

Peres GM, Mariana M, Cairrão E. Pre-eclampsia and eclampsia: An update on the pharmacological treatment applied in Portugal. J Cardiovasc Dev Dis. 2018;5(1):3.

Wei Q, Zhang L, Duan MF, Wang YM, Huang N, Song CR. Use of angiotensin II receptor blocker during pregnancy: A case report. Medicine (Baltimore). 2021;100(3):e2430.

Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30(3):160-164.

Malik BA, Momina SB, Ashraf T. Comparison between methyldopa and combination of methyldopa and nifedipine in terms of mean change in blood pressure in pregnancy induced hypertension. Pak J Med Health Sci. 2021;15(7):1703-1705. doi:10.53350/pjmhs211571703.

Ju G, Chen L, Wang R, Zhang L, Liu Z, Chen S. A disproportionality analysis of nifedipine in the overall population and in pregnant women using the FDA Adverse Event Reporting System (FAERS) database. Medicine (Baltimore). 2025;104(44):e45113.

IBM Corp. IBM SPSS Statistics for Windows, Version 25.0 [software]. Armonk (NY): IBM Corp; 2017.

Food and Drug Administration (US). Pregnancy and Lactation Labeling Final Rule (PLLR) [Internet]. Silver Spring (MD): US Food and Drug Administration; 2014 [cited 2024 Jul 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/biologics-rules/pregnancy-and-lactation-labeling-final-rule

Therapeutic Goods Administration. Prescribing medicines in pregnancy database [Internet]. Canberra (AU): Australian Government Department of Health and Aged Care [cited 2024 Aug 10]. Available from: https://www.tga.gov.au/resources/health-professional-information-and-resources/australian-categorisation-system-prescribing-medicines-pregnancy/prescribing-medicines-pregnancy-database.

DOI: https://doi.org/10.24198/ijpst.v13i2.67628